Universitätsklinikum Schleswig-Holstein (UKSH)
Postdoc (m/w/*) Position in Microbial Metabolism in IBD (DFG FOR5042 miTarget)
The Institute of Clinical Molecular Biology is focused on the understanding of the pathophysiology of chronic inflammatory disease, namely inflammatory bowel disease and has contributed in the recent to the molecular understanding how IBD risk genes transform into chronic intestinal inflammation in human. The Institute is one of the core research centres in various national and international research alliances (e.g. DFG ExC, BMBF consortia iTREAT, GUIDE-IBD and Try-IBD, H2020 SYSCID, IMI2 3TR and ImmUniverse).
We are looking for professional and competent support as early as possible. One Post Doc position is available at the Institute of Clinical Molecular Biology.
Our lab focuses on the role of host-microbial interaction and instruction of intestinal immunity in the context of intestinal inflammation. We are investigating how IBD risk genes (e.g. ATG16L1, XBP1) promote epithelial cell dysfunction in the context of intestinal inflammation (Nature 2013, Journal of Experimental Medicine 2018, Science 2019) and intestinal carcinogenesis (Nature 2016, Gastroenterology 2018). We employ omics-based approaches to identify novel immunometabolic principles in the pathogenesis of IBD (Gut 2019, Gastroenterology 2019). The advertised position will work within a DFG funded research framework (miTarget) elucidating the role of the microbial metabolism a potential therapeutic target in inflammatory bowel disease.
We are interested in recruiting self-motivated individuals with a desire to succeed and complement the internationally competitive research activities and highly interdisciplinary team of the laboratory. Research will include the development of large-scale metabolic profiling in IBD patient cohorts and the identification of microbial metabolic signatures that drive disease pathophysiology.
Essential criteria include expertise in LC-MS-based metabolomics, knowledge in bioinformatics and -statistics and experience in programming. Scientific cross-disciplinary thinking is anticipated in order to communicate across with scientist across various backgrounds (immunology, microbiology, biochemistry).
The initial contract is limited until February 29, 2024 with the intent to prolong. The salary will be based on the German E13 TV-L scale (100%) if terms and conditions under collective bargaining law are fulfilled. The preferred starting date is as soon as possible.
We offer an excellent and exciting multidisciplinary team-oriented research environment and opportunities to being part of the national and international scientific community. Our scientist are encouraged to attend international conferences and visit cooperation partners. We offer flexible working hours and various opportunities to reconcile work and family life.
The UKSH has been certified as a family-friendly institution and is committed to further improve the compatibility of work and family life. The University supports the employment of disabled persons. Persons with disabilities will, with appropriate qualifications and aptitudes, be employed preferentially. The UKSH has set the goal to reach professional equality between men and women. The University aims to increase the number of women among the faculty staff and therefore explicitly encourages the application of female scientists.
Dr. Konrad Aden, Institute of Clinical Molecular Biology at the University Hospital Schleswig-Holstein, Campus Kiel, Phone: +49-431-500-15111, email@example.com
The application deadline is December 17, 2020. Please mention our reference number at your application.
To apply for this job please visit jobs.uksh.de.